TY - JOUR T1 - Platelet indices: a new tool for monitoring infantilehemangioma treatment TT - Trombosit indeksleri: infantil hemanjiom tedavisinin izlenmesinde yeni bir araç AU - Ünal, Ekrem AU - Akyol, Şefika AU - Göl, Deniz Koçak AU - Özcan, Alper AU - Gök, Veysel AU - Demir, Baver AU - Yılmaz, Ebru AU - Karakükçü, Musa PY - 2025 DA - March Y2 - 2025 DO - 10.47582/jompac.1643407 JF - Journal of Medicine and Palliative Care JO - J Med Palliat Care / JOMPAC / Jompac PB - MediHealth Academy Yayıncılık WT - DergiPark SN - 2717-7505 SP - 105 EP - 109 VL - 6 IS - 2 LA - en AB - Aims: Infantile hemangioma (IH) is the most common benign vascular tumor in childhood. Diagnosis, treatment decisionmaking, and monitoring of the treatment are challenging. This study aims to investigate the utilization of platelet (PLT) indices as a marker in the follow-up of IH treatment.Methods: The patients who were admitted and followed up in the outpatient clinic of Erciyes University Department of Pediatric Hematology and Oncology were enrolled in the study. The demographical data, treatment results, and PLT indices of the patients at certain time points were analyzed retrospectively. PLT, mean platelet volume (MPV), and platelet distribution width (PDW) were measured at various time points: upon admission, after the first and second months of treatment, at treatment completion, and during rebound episodes in affected patients.Results: A general decrease in PLT, PDW, and MPV values was noted when comparing admission levels to the first month of treatment. The mean PLT count was 452.680/mm3 at admission, it decreased to 405.900/mm3 at the 1st month, 376.600/mm3 at the 2nd month and 359.900/mm3 at the end of treatment (p: 0,002). Besides MPV was evaluated, it was observed that while the mean was 10.43 fl at the time of admission, it decreased to 9.51 fl in the following months and the decline was statistically significant with a p value of 0,031. Lastly, regarding the mean PDW values, a decline was detected once again from 11.34 % to 10.2 % between the admission time and termination of the treatment with a statistically significant p value of KW - Infantile hemangioma KW - platelet indices KW - propranolol treatment N2 - Amaçlar: İnfantil hemanjiyom (İH), çocukluk çağında en sık görülen benign vasküler tümördür. Tanı, tedavi kararı ve tedavinin izlenmesi zordur. Bu çalışmanın amacı trombosit (PLT) indekslerinin IH tedavisinin takibinde bir belirteç olarak kullanımını araştırmaktır.Yöntemler: Çalışmaya …….. Üniversitesi Pediatrik Hematoloji ve Onkoloji Anabilim Dalı polikliniğine başvuran ve takip edilen hastalar dahil edildi. Hastaların demografik verileri, tedavi sonuçları ve belirli zaman noktalarındaki PLT indeksleri retrospektif olarak analiz edildi.Sonuçlar: PLT, ortalama trombosit hacmi (MPV) ve trombosit dağılım genişliği (PDW) yatışta, tedavinin birinci ve ikinci aylarından sonra, tedavi tamamlandığında ve etkilenen hastalarda rebound atakları sırasında ölçüldü. Başvurudaki seviyeleri tedavinin birinci ayıyla karşılaştırıldığında PLT, PDW ve MPV değerlerinde genel bir azalma kaydedildi. Beklendiği gibi, tüm trombosit indeksleri bu dönemde düşüş eğilimi gösterdi. Ek olarak, tedavinin birinci ve ikinci ayları arasında PDW ve MPV'de istatistiksel olarak anlamlı farklılıklar belirlendi.Sonuç: IH hastalarının %15'ine kadarı komplikasyonlar nedeniyle tedaviye ihtiyaç duyabilir. Bu çalışma, PLT, PDW ve MPV değerlerinin tedavi yanıtını değerlendirmek ve klinik karar almaya rehberlik etmek için değerli biyobelirteçler olarak hizmet edebileceğini vurgulamaktadır. CR - Eisenstein KA. Infantile hemangiomas: a review and future opportunities. Mo Med. 2023;120(1):49-52. CR - Hemangioma Investigator Group, Haggstrom AN, Drolet BA, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007;150(3):291-294. doi:10.1016/j.jpeds.2006.12.003 CR - Cazeau C, Blei F, Gonzáles Hermosa MDRF, et al. Burden of infantile hemangioma on family: an international observational cross-sectional study. Pediatr Dermatol. 2017;34(3):295-302. doi:10.1111/pde.13133 CR - Surlis T, De Sa Reilly H, Sadlier M, Nelson J. Infantile haemangiomas. BMJ. 2022;378:e068734. doi:10.1136/bmj-2021-068734 CR - Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1): e20183475. doi:10.1542/peds.2018-3475 CR - Broeks IJ, Hermans DJ, Dassel AC, van der Vleuten CJ, van Beynum IM. Propranolol treatment in life-threatening airway hemangiomas: a case series and review of literature. Int J Pediatr Otorhinolaryngol. 2013; 77(11):1791-1800. doi:10.1016/j.ijporl.2013.08.011 CR - Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128-140. doi:10.1542/peds.2012-1691 CR - Nazemian S, Sharif S, Childers ELB. Infantile hemangioma: a common lesion in a vulnerable population. Int J Environ Res Public Health. 2023; 20(8):5585. doi:10.3390/ijerph20085585 CR - Jacobs AH. Strawberry hemangiomas; the natural history of the untreated lesion. Calif Med. 1957;86(1):8-10. CR - Surlis T, De Sa Reilly H, Sadlier M, Nelson J. Infantile haemangiomas. BMJ. 2022;378:e068734. doi:10.1136/bmj-2021-068734 CR - Gnarra M, Behr G, Kitajewski A, et al. History of the infantile hepatic hemangioma: from imaging to generating a differential diagnosis. World J Clin Pediatr. 2016;5(3):273-280. doi:10.5409/wjcp.v5.i3.273 CR - Tiemann L, Hein S. Infantile hemangioma: a review of current pharmacotherapy treatment and practice pearls. J Pediatr Pharmacol Ther. 2020;25(7):586-599. doi:10.5863/1551-6776-25.7.586 CR - McGee P, Miller S, Black C, Hoey S. Propranolol for infantile haemangioma: a review of current dosing regime in a regional paediatric hospital. Ulster Med J. 2013;82(1):16-20. CR - Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124(3):e423-e431. doi: 10.1542/peds.2008-3458 CR - Greenberger S, Bischoff J. Pathogenesis of infantile haemangioma. Br J Dermatol. 2013;169(1):12-19. doi:10.1111/bjd.12435 CR - Phung TL, Hochman M. Pathogenesis of infantile hemangioma. Facial Plast Surg. 2012;28(6):554-562. doi:10.1055/s-0032-1329930 CR - Eroglu N, Sen HS, Kar YD, Pektas A, Eker I. Can propranolol affect platelet indices in infantile hemangioma? J Pediatr Hematol Oncol. 2023;45(7):e899-e903. doi:10.1097/MPH.0000000000002683 CR - Weksler BB, Gillick M, Pink J. Effect of propranolol on platelet function. Blood. 1977;49(2):185-196. doi:10.1182/blood.V49.2.185.185 CR - Ring ME, Corrigan JJ Jr, Fenster PE. Antiplatelet effects of oral diltiazem, propranolol, and their combination. Br J Clin Pharmacol. 1987;24(5):615-620. doi:10.1111/j.1365-2125.1987.tb03220.x CR - Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review. Ann Med. 2012;44(8):805-816. doi:10.3109/ 07853890.2011.653391 CR - Şen HS, Yalçın B, Canpınar H, Ocak S, Akyüz C. Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol. Turk J Pediatr. 2020;62(6):979-985. doi:10.24953/turkjped.2020.06.009 UR - https://doi.org/10.47582/jompac.1643407 L1 - https://dergipark.org.tr/tr/download/article-file/4625430 ER -